

FBXL4 RABBIT PAB

货号: S222020

产品全名: FBXL4 兔多抗

基因符号: FBL4; FBL5; MTDPS13

UNIPROT ID: Q9UKA2 (Gene Accession - NP_036292)

背景: This gene encodes a member of the F-box protein family, which are characterized by an approximately 40 amino acid motif, the F-box. F-box proteins constitute one subunit of modular E3 ubiquitin ligase complexes, called SCF complexes, which function in phosphorylation-dependent ubiquitination. The F-box domain mediates protein-protein interactions and binds directly to S-phase kinase-associated protein 1. In addition to an F-box domain, the encoded protein contains at least 9 tandem leucine-rich repeats. The ubiquitin ligase complex containing the encoded protein may function in cell-cycle control by regulating levels of lysine-specific demethylase 4A. Alternative splicing results in multiple transcript variants.

抗原: Synthetic peptide of human FBXL4

经过测试的应用: ELISA, IHC

推荐稀释比: IHC: 30-150; ELISA: 5000-10000

种属反应性: Rabbit

克隆性: Rabbit Polyclonal

亚型: Immunogen-specific rabbit IgG


纯化: Antigen affinity purification

种属反应性: Human, Mouse


成分: PBS (without Mg²⁺ and Ca²⁺), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

研究领域: Cell Biology


储存和运输: Store at -20°C. Avoid repeated freezing and thawing




Immunohistochemistry analysis of paraffin embedded Human ovarian cancer tissue using 222020(FBXL4 Antibody) at a dilution of 1/25(Cytoplasm and Nucleus).



In comparison with the IHC on the left, the same paraffin-embedded Human ovarian cancer tissue is first treated with the synthetic peptide and then with 222020(Anti-FBXL4 Antibody) at dilution 1/25.



The image on the left is immunohistochemistry of paraffin-embedded Human breast cancer tissue using 222020(Anti-FBXL4 Antibody) at a dilution of 1/25.



In comparison with the IHC on the left, the same paraffin-embedded Human breast cancer tissue is first treated with synthetic peptide and then with D268894(Anti-FBXL4 Antibody) at dilution 1/25.



Product Description

Pioneering GTPase and Oncogene Product Development since 2010
